GlassScriptPhysician profile
Katharine Ann Buck
NPI 1376159145
$11,319.25
in general payments reported to CMS, 2019-2025
27 companies · $4,056 in 2025
The $4,056 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,409 · 2023: $2,416 · 2024: $3,439 · 2025: $4,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,910.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,460.04 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,446.77 | 2022-2025 | |
| Amgen INC. | $1,147.69 | 2022-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,132.10 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $939.10 | 2022-2025 | |
| Lilly USA, LLC | $778.93 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $596.30 | 2022-2025 | |
| Dexcom, INC. | $543.07 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $458.36 | 2024-2025 | Jardiance |
| Pfizer INC. | $416.87 | 2022-2025 | |
| Daiichi Sankyo INC. | $386.06 | 2024-2025 | Injectafer |
| Glaxosmithkline, LLC. | $366.64 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $265.05 | 2025 | Auvelity |
| Corcept Therapeutics | $231.11 | 2024-2025 | Korlym |
| Sumitomo Pharma America, INC. | $208.68 | 2023-2025 | Gemtesa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $177.36 | 2022-2024 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $136.80 | 2024-2025 | Vowst, Zenpep |
| Exact Sciences Corporation | $136.14 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $111.16 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.79 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $71.10 | 2023-2025 | Rexulti |
| Eisai INC. | $63.52 | 2024 | |
| Boston Scientific Corporation | $52.49 | 2023-2025 | General - Therapies, Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.47 | 2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $28.14 | 2022 | |
| Dynavax Technologies Corporation | $20.38 | 2024 | Heplisav-B |
| Averitas Pharma INC. | $20.13 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katharine Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.